Maximizing the value of the open label extension phase of randomized clinical trials
J Nephrol
.
2023 Jul;36(6):1561-1563.
doi: 10.1007/s40620-022-01542-3.
Epub 2023 Jan 6.
Authors
Howard Trachtman
1
,
Rosanna Coppo
2
,
Moin Saleem
3
,
Alex Mercer
4
,
Radko Komers
5
Affiliations
1
Department of Pediatrics, University of Michigan, 1150 W. Medical Center Dr, Med Sci 1/ARF 2511, Ann Arbor, MI, 48109-0168, USA.
[email protected]
.
2
Fondazione Ricerca Molinette, Ospedale Regina Margherita, Turin, Italy.
3
Children's Renal Unit, Bristol Medical School, University of Bristol, Bristol, UK.
4
JAMCO Pharma Consulting AB, Enskede, Sweden.
5
Travere Therapeutics, Inc., San Diego, CA, USA.
PMID:
36607562
PMCID:
PMC9817433
DOI:
10.1007/s40620-022-01542-3
No abstract available
MeSH terms
Double-Blind Method
Humans
Randomized Controlled Trials as Topic*
Treatment Outcome
Grants and funding
MR/R013942/1/MRC_/Medical Research Council/United Kingdom